Emergent BioSolutions Inc. — Director's Dealing 2023

Feb 11, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2023-02-08

Reporting Person: Kramer Robert (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-08	Common Stock	A	278	—	Acquired	114487	Direct
2023-02-08	Common Stock	F	4944	$13.25	Disposed	109543	Direct

Footnotes

F1: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2022 fiscal year, as certified by the Compensation Committee following the performance period. On February 08, 2023, the final certification date, the Compensation Committee certified the achievement of the 2020-2022 PSUs at a payout factor of 101.67% of target resulting in the actual award of 16,961 shares of common stock, which is in excess of the 16,683 shares previously reported on February 25, 2020.

F2: Represents shares of common stock withheld to pay taxes.